Astrazeneca (NYSE:AZN) Lowered to “Hold” Rating by Wall Street Zen

by · The Markets Daily

Astrazeneca (NYSE:AZN – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Thursday.

Astrazeneca Stock Up 0.6%

Shares of AZN opened at $194.42 on Thursday. Astrazeneca has a 52 week low of $122.48 and a 52 week high of $212.71.

About Astrazeneca

(Get Free Report)

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

See Also